Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model

Cephalalgia. 2023 Apr;43(4):3331024231163131. doi: 10.1177/03331024231163131.

Abstract

Background: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multipotent neuropeptide widely distributed in the trigeminovascular system (TVS) and higher brain regions. At present, the underlying mechanism of PACAP/PACAP type1 (PAC1) receptor in migraine generation remains unclear.

Methods: The rat model of chronic migraine (CM) was established by repeated intraperitoneal injection of nitroglycerin (NTG). Von Frey filaments and hot plate tests were used to measure the mechanical and thermal thresholds. The expression levels of c-Fos, calcitonin gene-related peptide (CGRP), PACAP, PAC1, protein kinase A (PKA) and phosphorylated extracellular signal-regulated kinase (ERK) were assessed by western blotting or immunofluorescence staining. The internalization of PAC1 receptor was visualized by fluorescence microscope and laser scanning confocal microscope.

Results: The results showed that c-Fos and CGRP expression significantly increased after repeated administrations of NTG or PACAP. Pitstop2 notably improved hyperalgesia in CM rats, while PACAP6-38 offered no benefit. In addition, PACAP-induced PAC1 receptor internalization, PKA and ERK pathways activation were blocked by Pitstop2 instead of PACAP6-38.

Conclusions: Our results demonstrate that inhibition of PAC1 receptor internalization could effectively improve allodynia in CM rats by restraining ERK signaling pathway activation in a chronic migraine rat model. Modulation of receptor internalization may be a novel perspective to explore specific mechanisms of PACAP signaling activation in the trigeminal vascular system.

Keywords: PAC1 receptor; PACAP; Pitstop2; migraine; receptor internalization.

MeSH terms

  • Animals
  • Calcitonin Gene-Related Peptide / metabolism
  • Extracellular Signal-Regulated MAP Kinases
  • Hyperalgesia
  • MAP Kinase Signaling System
  • Migraine Disorders*
  • Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism
  • Pituitary Adenylate Cyclase-Activating Polypeptide / pharmacology
  • Rats
  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I* / metabolism

Substances

  • Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
  • Extracellular Signal-Regulated MAP Kinases
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Calcitonin Gene-Related Peptide